Key facts
- Allegro’s last known valuation is $66.1M (May 2023).
- It has raised $12.2M; the latest was Early Stage VC ($2.3M) in Jul 2025.
- Notable investors include Noshaq, Jurgen Ingels, Annie Vereecken, BlueChem, HERAN Partners — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Allegro
- ·The full record, as it builds
Funding rounds
No funding rounds for Allegro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Allegro
Developer of a performance biopolymer-based injectable designed to modify osteoarthritis by restoring the natural protective mechanics of the joint. The company offers a novel biopolymer technology that reinforces joint biomechanics and targets the underlying cause of degeneration, enabling patients with osteoarthritis and high-demand populations such as athletes, improved joint function and long-term disease management.
- Sector
- Healthcare
- HQ
- Antwerp, Belgium
- Founded
- 2021
- Employees
- 12
- Website
- allegro.bio/
- Ownership
- Privately Held (backing)
Allegro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allegro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allegro in its N-PORT filings yet. We sweep new filings monthly.